No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Tiger Shark Cervical Spacer System: FDA Provides Additional 510(k) Clearance

Editor: What To Know

  • “We have had great success with our Tiger Shark Cervical Spacer System thus far and we are excited to see where the line extension takes us to support more surgeons and their patients,” said Anderson Collins, Vice President of Business Development and International.
  • We believe that our exclusive focus on manufacturing provides us with a unique understanding of the opportunities and challenges faced by companies in the sector.
  • We utilize a patient, thoughtful investment approach and seek to partner with the management teams of our operating companies to achieve growth.

January 25, 2021

Tiger Shark Cervical Spacer System is comprised of titanium alloy and constructed into an anatomical form, complementing the shape of vertebral bodies. The implant features our BioBond™ endplate coverage creating an ideal micro surface for fusion.

The Tiger Shark Cervical Spacer System has experienced great success since inception in 2018. ChoiceSpine is thrilled to announce 510(k) clearance, adding additional footprint sizes that enhance the ability to treat a wider variety of patient anatomies. “We have had great success with our Tiger Shark Cervical Spacer System thus far and we are excited to see where the line extension takes us to support more surgeons and their patients,” said Anderson Collins, Vice President of Business Development and International.

“The additional size offering for Tiger Shark Cervical Spacer System allows me to offer a more bespoke fit for patients with larger vertebral body endplate anatomy,” stated Matthew Hazzard, MD of Northside Hospital in Georgia.

ChoiceSpine LLC, is a spinal device company located in Knoxville, TN and is privately held by Altus Capital Partners. The company prides itself on providing excellent products and exceptional service to meet the needs of their customers. ChoiceSpine offers a breadth of innovative and surgeon focused systems that are designed to be safe, efficient, and easy-to-use. By working closely with physicians and maintaining a service-focused distribution, ChoiceSpine will continue to bring technically superior spinal products to market.

Altus Capital Partners is a private equity firm that makes control investments in middle market manufacturing businesses. We believe that our exclusive focus on manufacturing provides us with a unique understanding of the opportunities and challenges faced by companies in the sector. We utilize a patient, thoughtful investment approach and seek to partner with the management teams of our operating companies to achieve growth. With offices in Wilton, CT and Lincolnshire, IL, Altus Capital Partners has completed 18 platform investments and numerous add on acquisitions since 2003.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy